<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30810667</article-id><article-id pub-id-type="pmc">6385830</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0310</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Relationships Between Phenotype and Function of Blood CD4<sup>+</sup>
T-Cells and Ascending Thoracic Aortic Aneurysm: an Experimental
Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sbrana</surname><given-names>Silverio</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1345-3223</contrib-id><name><surname>Tiwari</surname><given-names>Kaushal Kishore</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="c1"/><role>MD, MS, PhD</role></contrib><contrib contrib-type="author"><name><surname>Bevilacqua</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Giungato</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="aff5">5</xref><role>BSc, PhD</role></contrib><contrib contrib-type="author"><name><surname>Kallushi</surname><given-names>Enkel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Solinas</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Mazzone</surname><given-names>Anna Maria</given-names></name><xref ref-type="aff" rid="aff6">6</xref><role>MD, FESC</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Flow Cytometry Laboratory, CNR Institute of Clinical Physiology,
Massa, Italy. </aff><aff id="aff2">
<label>2</label> Cardiac Surgery Department "G. Pasquinucci" Heart Hospital, "G.
Monasterio" Foundation, Massa, Italy. </aff><aff id="aff3">
<label>3</label> Institute of Life Sciences, Scuola Superiore S. Anna, Pisa, Italy. </aff><aff id="aff4">
<label>4</label> Department of Cardiothoracic and Vascular Surgery, College of
Medical Sciences, Teaching Hospital, Bharatpur, Chitwan, Nepal. </aff><aff id="aff5">
<label>5</label> Cellular Biology Laboratory, CNR Institute of Biomedical
Technologies, Pisa, Italy. </aff><aff id="aff6">
<label>6</label> Cardiology Department "G. Pasquinucci" Heart Hospital, "G.
Monasterio" Foundation, Massa, Italy. </aff><author-notes><corresp id="c1">Correspondence Address: <bold>Kaushal K. Tiwari</bold>,
http://orcid.org/0000-0002-1345-3223, Department of Cardiothoracic and Vascular
Surgery, College of Medical Sciences, Teaching Hospital, P.O. Box 23,
Bharatpur-10, Chitwan, Nepal - Zip Code: 44207. E-mail:
<email>drkaushalkt@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2019</year></pub-date><volume>34</volume><issue>1</issue><fpage>8</fpage><lpage>16</lpage><history><date date-type="received"><day>01</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>02</day><month>10</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Non-familial ascending thoracic aorta dilation and aneurysms (TAAs) are
silent diseases in elderly patients. Histopathology revealed that
functionally polarized infiltrating CD4<sup>+</sup> T-cells play a key role
in aortic wall weakening.</p></sec><sec><title>Objective</title><p>To evaluate the possible associations between phenotype and cytokine
production of circulating CD4<sup>+</sup> T-lymphocytes and the presence of
TAA in patients with aortic valve disease (AVD).</p></sec><sec><title>Methods</title><p>We studied blood samples from 10 patients with TAA and 10 patients with AVD.
Flow cytometry was used to quantify: a) CD4<sup>+</sup> T-lymphocytes
surface expression of CD25, CD28, and chemokine receptors (CCR5, CXCR3,
CX3CR1); b) fractions of <italic>in vitro</italic> stimulated
CD4<sup>+</sup> T-cells producing cytokines (interferon gamma
[IFN-&#x003b3;], interleukin [IL]-17A, IL-21, IL-10); c)
CD4<sup>+</sup>CD25<sup>high</sup>FoxP3<sup>+</sup> regulatory T-cells
(Treg) fraction. Enzyme-linked immunosorbent assays (ELISA) were performed
for cytokines (IFN-&#x003b3;, IL-6, IL-10, IL-17A, IL-23, transforming growth
factor beta [TGF-&#x003b2;]) and chemokines (RANTES, CX3CL1).</p></sec><sec><title>Results</title><p>The total
CD4<sup>+</sup>CD28<sup>&#x000b1;</sup>CD4<sup>+</sup>/CX3CR1<sup>+</sup>
T-cells fraction was higher (<italic>P</italic>=0.0323) in AVD
(20.452&#x000b1;4.673) than in TAA patients (8.633&#x000b1;2.030). The
frequency ratio of CD4<sup>+</sup> T-lymphocytes producing IFN-&#x003b3;
<italic>vs</italic>. IL-17A+IL-21 cytokine-producing CD4+ T-cells was
higher (<italic>P</italic>=0.0239) in AVD (2.102&#x000b1;0.272) than in TAA
(1.365&#x000b1;0.123) patients. The sum of
CD4<sup>+</sup>CD28<sup>&#x000b1;</sup>CD4<sup>+</sup>/CX3CR1<sup>+</sup>
T-cells correlated positively with values of the previous cytokine ratio
(<italic>P</italic>=0.0002, R=0.732). The ratio of
CD4<sup>+</sup>CD28<sup>&#x000b1;</sup>CD4<sup>+</sup>/CX3CR1<sup>+</sup>
T-cells <italic>vs</italic>. Treg was higher (<italic>P</italic>=0.0008) in
AVD (20.859&#x000b1;3.393) than in TAA (6.367&#x000b1;1.277) patients.</p></sec><sec><title>Conclusion</title><p>Our results show that the presence of TAA in subjects with AVD is associated
with imbalance between phenotypic and cytokine-producing subsets of
circulating CD4+ T-lymphocytes, prevalently oriented towards a pro-fibrotic
and IFN-&#x003b3; counteracting effect to functional polarization.</p></sec></abstract><kwd-group><kwd>Aortic Aneurysm, Thoracic</kwd><kwd>CD4-Positive T-Lymphocytes</kwd><kwd>Flow Cytometry</kwd></kwd-group><funding-group><award-group><funding-source>National Research Council (CNR) of Italy</funding-source><award-id>DG.RSTL.035.006-035</award-id></award-group><funding-statement>Financial support: This study was funded by the National Research
Council (CNR) of Italy, RSTL (Curiosity Driven Research Program)
DG.RSTL.035.006-035.</funding-statement></funding-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Angiotensin-converting
enzyme</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">K<sub>3</sub>-EDTA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Tripotassium
ethylenediaminetetraacetic acid</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ANOVA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Analysis of
variance</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Myofibroblasts</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">APC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Antigen-presenting
cells</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Phycoerythrin</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AVD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Aortic valve
disease</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PMA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Phorbol myristate
acetate</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Aortic valve
replacement</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RPMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Roswell Park Memorial
Institute</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Cy5</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cyanine 5</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SEM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard errors of the
mean</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ECM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Extracellular
matrix</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SSC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Side scatter</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ELISA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Enzyme-linked
immunosorbent assay</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Thoracic aortic
aneurysm</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FITC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Fluorescein
isothiocyanate</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Thoracic aortic surgery
for aneurysm</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FoxP3</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Forkhead-box-P3</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TGF-&#x003b2;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transforming growth
factor beta</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IFN-&#x003b3;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interferon gamma</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Treg</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Regulatory T-cells</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interleukin</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">WBC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= White blood cells</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>The non-familial ascending thoracic aortic dilatations and thoracic aortic aneurysms
(TAA) are frequent in individuals older than 65 years of age (approximately 6-9%),
with a risk of rupture or dissection ranging from 2 to 3.5 cases per 100,000
patients/year<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>The progression from aortic dilatation to aneurysm is a multifactorial process
partially undiscovered. Besides other well-known mechanisms<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>, the role of chronic
immune-mediated inflammations in defining biomechanical properties of the aortic
wall is still to be determined. In particular, the study of cellular and molecular
mechanisms leading to aortic fibrosis, considered the histopathological marker of an
altered vascular remodeling process<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>, might be an important target in understanding
the individual's susceptibility to non-syndromic ascending thoracic aortic
dilatation and TAA formation. Recent findings in humans confirmed the key role of
myofibroblasts (MF) in the extracellular matrix (ECM) proteolysis and deposition
(fibrosis)<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. MF activity is modulated by a wide array of pro-
and anti-fibrotic cytokines and growth factors released by mononuclear immune cells
infiltrating the inflamed tissue<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Especially, the cytokines produced by
CD4<sup>+</sup> T-lymphocytes play a causative role in the initiation and
progression of fibrosis associated with pathological conditions such as systemic
sclerosis, atherosclerosis, and the use of silicone mammary
implants<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Given the crucial role of distinct CD4<sup>+</sup>
T-lymphocyte subsets in normal immune-regulation<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>, the evaluation of their
dynamic functional balance in terms of cell frequency ratio, either expressing a
particular surface phenotype or producing selective signature cytokines, is an
important tool to investigate whether a clinical pathological condition and its
outcome are associated with a particular T-helper functional
perturbation<sup>[<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>To our knowledge, so far, no studies have related phenotype and function of
peripheral blood CD4<sup>+</sup> T-lymphocytes with the presence of TAA. Therefore,
we have evaluated the presence of possible relationships between this pathological
condition and: a) the expression of chemokine receptors and activation markers
(CCR5, CXCR3, CX3CR1, CD25) on total blood CD4<sup>+</sup> T-cell and on the
pro-inflammatory/cytotoxic subset CD4<sup>+</sup>CD28<sup>-</sup>, known to be
involved in vascular inflammation<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>; b) the cytokine production (interferon gamma
[IFN-g, interleukin [IL]-17A, IL-21, IL-10) by <italic>in vitro</italic> stimulated
CD4<sup>+</sup> T-cells. Moreover, given their both beneficial and harmful roles
in several clinical settings, including vascular injury<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>, we quantified the
circulating fraction of the CD4<sup>+</sup>CD25<sup>high</sup>FoxP3<sup>+</sup>
naturally occurring regulatory T-cells (Treg). On this basis, newly established
phenotypic and functional blood CD4<sup>+</sup> T-lymphocyte ratios, that overcome
the traditional Th1/Th2 paradigm<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>, have been calculated and related to the
presence of an aortic aneurysm. We also measured the circulating levels of several
cytokines (IFN-&#x003b3;, IL-6, IL-10, IL-17A, IL-23, transforming growth factor beta
[TGF-&#x003b2;]) and chemokines (RANTES, CX3CL1) known to influence CD4<sup>+</sup>
T-cells function and migration<sup>[<xref rid="r13" ref-type="bibr">13</xref>-<xref rid="r15" ref-type="bibr">15</xref>]</sup>.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Patients and Blood Samples</title><p>We have enrolled 20 patients undergoing surgery for aortic valve disease (AVD).
TAA group (n=10) included patients undergoing aortic valve surgery with TAA
surgery and AVD group (n=10) included patients undergoing surgery only for AVD,
like stenosis or regurgitation, or both. Both groups underwent surgery by
aortotomy. All patients had an indication for aortic valve surgery, according to
current guidelines. TAA surgery was performed, if recommended by current
guidelines. Exclusion criteria were the presence of genetic disorders,
autoimmune and chronic inflammatory diseases, cancer, or hematological diseases.
We enrolled patients with normal, ectasic or entirely aneurysmatic ascending
aorta. Comorbidities, risk factors, and medical therapies were recorded, with
particular attention to statins and/or angiotensin-converting enzyme (ACE)
inhibitors, known to exert also immunomodulating effects<sup>[<xref rid="r16" ref-type="bibr">16</xref>-<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Mean and peak
aortic gradients were measured by Doppler echocardiography and used to define
the grade of stenosis. Aortic valve lesions were classified as predominant
stenosis (mean transvalvular gradient &#x02265;40 mmHg and grade of regurgitation
&#x0003c;3<sup>+</sup>/4<sup>+</sup>), predominant regurgitation (grade of
regurgitation 4<sup>+</sup>/4<sup>+</sup> and mean gradient &#x0003c;40 mmHg), and
steno-regurgitation, in other cases.</p><p>Venous blood was collected at the admission in Vacutainer tubes containing
tripotassium ethylenediaminetetraacetic acid (K<sub>3</sub>-EDTA) or
sodium-heparin as anticoagulants. Plasma was obtained after blood centrifugation
and immediately frozen at -80&#x000ba;C. The protocol was approved by the local ethics
committee and informed consent was obtained from each patient.</p></sec><sec><title>Data Acquisition and Analysis</title><p>Leukocyte count was carried out with a routine analyzer. Flow cytometry was
performed with a FACS scan instrument equipped with a CellQuest software (Becton
Dickinson). Quantification of lymphocyte surface markers expression and
intracellular cytokines content was based on measurement of fraction
(percentage) of positive events. Enzyme-linked immunosorbent assays (ELISA) were
performed using the ASYS HITECH Microplate Reader (Eugendorf).</p></sec><sec><title>Surface Staining</title><p>Blood samples were processed as previously described for monocyte
analysis<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. In brief, K<sub>3-E</sub>DTA samples were
treated with a red cell lysing solution to isolate leukocytes, and then stained
with the following combinations of phycoerythrin (PE)/cyanine 5 (Cy5) [PC5]-,
fluorescein isothiocyanate (FITC)-, and (PE)-conjugated monoclonal antibodies:
CD4/CD28/CD25; CD4/CD28/CCR5; CD4/CD28/CXCR3; CD4/CD28/CX3CR1. Isotype controls
were performed. The antibodies used were from Becton Dickinson, Pharmingen,
Immunotech, R&#x00026;D Systems, and MBL International Corporation. The acquisition
was stopped after 30,000 CD4<sup>+</sup> T-lymphocytes were collected for each
sample (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Identification of total CD4<sup>+</sup> and CD4<sup>+</sup>CD28-
T-lymphocyte subsets. Top: Selection of total CD4<sup>+</sup>
T-lymphocytes (R1) based on side scatter (SSC) properties and FL3
(CD4) bright fluorescence (A). R1-derived dot-plot of FL1 (CD28)
versus FL3 (CD4) used to identify and quantify (as percentage) the
CD4<sup>+</sup>CD28<sup>-</sup> T-lymphocyte fraction (R2) (B).
Bottom: Example of quantification of CX3CR1 expression. The overlay
of the FL2 fluorescence histograms is used to quantify the CX3CR1
positive cells (as percentage, events in M1, filled histograms) on
the selected total CD4<sup>+</sup> (R1 gated) (C) and
CD4<sup>+</sup>CD28- (R1 + R2 gated) (D) T-cell subsets, when
compared with isotype controls (dotted histograms).</p></caption><graphic xlink:href="rbccv-34-01-0008-g01"/></fig></p></sec><sec><title>Intracellular Cytokines</title><p>A whole blood staining procedure for intracellular cytokines detection was
carried out as described<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. In brief, heparinized samples were diluted
1:1 with RPMI (acronym for Roswell Park Memorial Institute) medium complete
medium and incubated at a density of 2x10<sup>6</sup> leukocytes/ml for 5 hours,
at 37&#x000ba;C. Phorbol myristate acetate (PMA) (Sigma Chemical Co.) (50 ng/ml) and
ionomycin (1 mg/ml) were used as <italic>in vitro</italic> activators, in the
presence of brefeldin A (eBioscience Inc.) (3 mg/ml final) as secretion blocking
agent. Samples were then recovered, treated with a red cell lysing solution, and
the isolated white blood cells (WBC) were stained with a combination of PC5- and
FITC-conjugated monoclonal antibodies against the markers CD3 and CD4,
respectively. Then, the cells were fixed with formaldehyde (2%) and
permeabilized with saponin (0.5%). Cytokine staining was performed with
PE-labeled monoclonal antibodies against IL-17A, IL-21, IFN-&#x003b3; and IL-10.
Isotype controls were performed. The acquisition was stopped after 30,000
CD3<sup>+</sup> T-lymphocytes were collected for each sample (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p><fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Analysis of intracellular interferon gamma (IFN-y) production by
CD4<sup>+</sup> T-lymphocytes in activated whole blood samples,
as example of cytokine-producing cells quantification by dot-plot
quadrant statistics. Top: Selection of CD3<sup>+</sup> T-lymphocytes
(R1) based on side scatter (SSC) properties and FL3 (CD3) bright
fluorescence (A). R1-derived dot-plot of FL2 (IFN-&#x003b3;) vs. FL1
(CD4) used to select the CD4<sup>+</sup> T-lymphocyte fraction (R2)
(B). Bottom: Quantification (as percentage) of CD4<sup>+</sup>
T-cells producing IFN-&#x003b3; (upper right quadrant, R1 + R2 gated)
(D), when compared with isotype control (upper right quadrant, R1 +
R2 gated) (C).</p></caption><graphic xlink:href="rbccv-34-01-0008-g02"/></fig></p></sec><sec><title>CD4<sup>+</sup>CD25<sup>high</sup>FoxP3<sup>+</sup> Regulatory
T-cells</title><p>Blood samples were processed as published<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, with minor modifications. In
brief, K<sub>3</sub>-EDTA samples were lysed as described before and the
isolated WBC stained with PC5- and PE-conjugated monoclonal antibodies against
the markers CD4 and CD25, respectively. Then, cells were fixed, permeabilized,
and stained with an Alexa Fluor 488-conjugated anti-human forkhead-box-P3
(FoxP3) monoclonal antibody (eBioscience Inc.). Isotype controls were performed.
Treg cells fraction was quantified into the 2% of
CD4<sup>+</sup>CD25<sup>high</sup> double positive events, as
reported<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. The acquisition was stopped after 30,000
CD4<sup>+</sup> T-lymphocytes were collected for each sample (<xref ref-type="fig" rid="f3">Figure 3</xref>).</p><p><fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Gating sequence used to quantify the frequency of regulatory T-cells
(Treg). Top: Identification of CD4<sup>+</sup> T-lymphocytes (R1)
based on side scatter (SSC) properties and FL3 (CD4) bright
fluorescence (A). R1-derived dot-plot of FL2 (CD25) vs. FL3 (CD4)
used to select the CD25<sup>high</sup> positive events at the top 2%
of CD4<sup>+</sup>CD25<sup>+</sup> T-cells (R2) (B). Bottom: The
overlay of Alexa Fluor-488 FL1 fluorescence histograms is used to
quantify the percentage of FoxP3<sup>+</sup> cells (events in M1,
filled histogram) (C), when compared with isotype control (dotted
histogram). By multiplying the above 2 percentages and dividing them
by 100, the CD4<sup>+</sup>CD25<sup>high</sup>FoxP3<sup>+</sup>
(Treg) cell fraction is calculated.</p></caption><graphic xlink:href="rbccv-34-01-0008-g03"/></fig></p></sec><sec><title>ELISA</title><p>Plasma levels of IFN-&#x003b3;, IL-6, IL-10, IL-17A, IL-23, TGF-&#x003b2;, RANTES,
and CX3CL1 were quantified by ELISA kits (R&#x00026;D Systems) according to the
manufacturer's protocol. Minimum detectable concentrations were 15.6 pg/ml
(IFN-&#x003b3;, 0.156 pg/ml (IL-6), 0.78 pg/ml (IL-10), 31.25 pg/ml (IL-17A),
39.0 pg/ml (IL-23), 0.031 ng/ml (TGF-&#x003b2;, 0.031 ng/ml (RANTES), and 0.156
ng/ml (CX3CL1).</p></sec><sec><title>Statistical Analysis</title><p>The calculation of mean values and standard errors of the mean (&#x000b1; SEM), as
well as the determination of linear correlations among continuous variables, was
carried out with the StatView 5.0 software. The existence of statistically
significant differences between groups was explored by analysis of variance
(ANOVA) Student's t-test for unpaired data. Chi-squares statistical analysis was
used for comparison between nominal variables. <italic>P</italic>&#x0003c;0.05 was
considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>General Findings</title><p>Mean aortic diameters were 35.50 &#x000b1; 1.65 mm (range 27-43 mm) and 48.90
&#x000b1; 1.18 mm (range 45-56 mm) in AVD and TAA groups, respectively
(<italic>P</italic>&#x0003c;0.0001). At the operation, 8 patients had an isolated
ascending aorta replacement and 2 underwent combined aortic root surgery.
Clinical and surgical characteristics of patients are reported in <xref rid="t1" ref-type="table">Table 1</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients' clinical characteristics (n=20).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="60%" span="1"/><col width="40%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Values (mean &#x000b1; SEM) or number (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">67.9&#x000b1;1.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (male)</td><td align="center" rowspan="1" colspan="1">12 (60%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker</td><td align="center" rowspan="1" colspan="1">11 (55%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity</td><td align="center" rowspan="1" colspan="1">7 (35%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">2 (10%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">13 (65%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin therapy</td><td align="center" rowspan="1" colspan="1">12 (60%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Angiotensin-converting enzyme inhibitors
therapy</td><td align="center" rowspan="1" colspan="1">6 (30%)</td></tr><tr><td colspan="2" align="left" rowspan="1">Predominant aortic valve pathology</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Bicuspid</td><td align="center" rowspan="1" colspan="1">6 (30%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Regurgitation</td><td align="center" rowspan="1" colspan="1">8 (40%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Stenosis</td><td align="center" rowspan="1" colspan="1">10 (50%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Steno-regurgitation</td><td align="center" rowspan="1" colspan="1">2 (10%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Mean gradient<xref ref-type="table-fn" rid="TFN1">*</xref> (mmHg)</td><td align="center" rowspan="1" colspan="1">51.50&#x000b1;2.70</td></tr><tr><td colspan="2" align="left" rowspan="1">Type of surgery</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Isolated AVR</td><td align="center" rowspan="1" colspan="1">10 (50%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;AVR + TAS</td><td align="center" rowspan="1" colspan="1">10 (50%)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p>Calculated in aortic stenosis and steno-regurgitation.</p></fn><fn id="TFN2"><p>AVR=aortic valve replacement; SEM=standard error of the mean;
TAS=thoracic aortic surgery for aneurysm</p></fn></table-wrap-foot></table-wrap><p>The mean frequency (&#x000b1; SEM) of CD4<sup>+</sup> T-lymphocytes was
46.39&#x000b1;1.99; their absolute number (number of cells/ml) was
953.34&#x000b1;61.85, accordingly with published CD4<sup>+</sup> T-cell reference
values during aging<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. The mean percentage (&#x000b1; SEM) of
CD4<sup>+</sup> T-cells belonging to the pro-inflammatory/cytotoxic subset
CD4<sup>+</sup>CD28<sup>-</sup> was 5.56&#x000b1;1.33; this value, if
referred to the age's range of our patients, is also in accord with literature
data<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. Cumulative analysis of surface markers
expression on total CD4<sup>+</sup> and CD4<sup>+</sup>CD28<sup>-</sup> T-cell
subsets are reported in <xref rid="t2" ref-type="table">Table 2</xref>.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Surface marker expression on blood total CD4<sup>+</sup>and
CD4<sup>+</sup>CD28- T-cell subsets (percentage of positivity, mean
&#x000b1;SEM) (20 patients).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">CD25</th><th align="center" rowspan="1" colspan="1">CCR5</th><th align="center" rowspan="1" colspan="1">CXCR3</th><th align="center" rowspan="1" colspan="1">CX3CR1</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total CD4<sup>+</sup></td><td align="center" rowspan="1" colspan="1">42.21&#x000b1;1.64</td><td align="center" rowspan="1" colspan="1">14.51&#x000b1;0.82</td><td align="center" rowspan="1" colspan="1">44.65&#x000b1;2.54</td><td align="center" rowspan="1" colspan="1">8.98&#x000b1;1.54</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4<sup>+</sup>CD28<sup>-</sup></td><td align="center" rowspan="1" colspan="1">3.98&#x000b1;2.64</td><td align="center" rowspan="1" colspan="1">28.65&#x000b1;2.42</td><td align="center" rowspan="1" colspan="1">71.75&#x000b1;3.70</td><td align="center" rowspan="1" colspan="1">91.77&#x000b1;1.45</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>SEM=standard error of the mean</p></fn></table-wrap-foot></table-wrap><p>The measurement of plasma cytokines/chemokines is reported in <xref rid="t3" ref-type="table">Table 3</xref>.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Blood levels of cytokines and chemokines (mean &#x000b1; SEM) (20
patients).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Mean &#x000b1; SEM</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IFN-&#x003b3; (pg/ml)</td><td align="center" rowspan="1" colspan="1">10.36&#x000b1;3.25</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-6 (pg/ml)</td><td align="center" rowspan="1" colspan="1">2.65&#x000b1;0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-17A (pg/ml)</td><td align="center" rowspan="1" colspan="1">13.51&#x000b1;2.37</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-23 (pg/ml)</td><td align="center" rowspan="1" colspan="1">20.76&#x000b1;3.90</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-10 (pg/ml)</td><td align="center" rowspan="1" colspan="1">0.55&#x000b1;0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">RANTES (ng/ml)</td><td align="center" rowspan="1" colspan="1">17.35&#x000b1;1.52</td></tr><tr><td align="left" rowspan="1" colspan="1">TGF-&#x003b2; (ng/ml)</td><td align="center" rowspan="1" colspan="1">6.59&#x000b1;0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">CX3CL1 (ng/ml)</td><td align="center" rowspan="1" colspan="1">0.47&#x000b1;0.02</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>IFN-&#x003b3;=interferon gamma; IL=interleukin; SEM=standard error of
the mean; TGF &#x003b2;=transforming growth factor beta</p></fn></table-wrap-foot></table-wrap><p>No relationship has been found between the plasma levels of cytokines/chemokines
and CD4<sup>+</sup> T-cells phenotypes, intracellular cytokines levels, and
presence of TAA, respectively. Cumulative quantification of intracellular
cytokines is reported in <xref rid="t4" ref-type="table">Table 4</xref>; also,
these data are in accordance with published T-cell cytokines levels in normal
aging<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Intracellular cytokine production by "<italic>in vitro</italic>"
stimulated CD4<sup>+</sup> T-lymphocytes in whole blood samples
(percentage of positivity, mean &#x000b1; SEM) (20 patients).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">IFN-&#x003b3;</th><th align="center" rowspan="1" colspan="1">IL-10</th><th align="center" rowspan="1" colspan="1">IL-17A</th><th align="center" rowspan="1" colspan="1">IL-21</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T-cells</td><td align="center" rowspan="1" colspan="1">24.84&#x000b1;3.13</td><td align="center" rowspan="1" colspan="1">2.70&#x000b1;0.38</td><td align="center" rowspan="1" colspan="1">1.86&#x000b1;0.22</td><td align="center" rowspan="1" colspan="1">14.02&#x000b1;1.46</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>IFN-&#x003b3;=interferon gamma; IL=interleukin; SEM=standard error of
the mean</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Relationships among CD4<sup>+</sup> T-cells Phenotypic Subsets</title><p>The accumulation of CD28<sup>-</sup> T-cells in aging is driven by a repeated
cellular activation, leading also to a modulation of CD4<sup>+</sup> T-cells
chemokine receptors expression<sup>[<xref rid="r24" ref-type="bibr">24</xref>,<xref rid="r26" ref-type="bibr">26</xref>]</sup>. In our patients, a tightly positive
correlation between the circulating fraction of CD4<sup>+</sup>CD28<sup>-</sup>
T-cells and the frequency of CD4<sup>+</sup> T-lymphocytes carrying the
fractalkine receptor CX3CR1 (CD4<sup>+</sup>/CX3CR1<sup>+</sup>)
(<italic>P</italic>&#x0003c;0.0001, R=0.934) has been observed.</p></sec><sec><title>Relationships among CD4<sup>+</sup> T-cells Phenotype/Function and
TAA</title><p>The sum of blood CD4<sup>+</sup>CD28&#x000b1;CD4<sup>+</sup>/CX3CR1<sup>+</sup>
T-cells fractions was significantly lower in the TAA group than in the AVD group
(<xref ref-type="fig" rid="f4">Figure 4</xref>).</p><p><fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Total fraction (percentage) of circulating
CD4<sup>+</sup>CD28<sup>&#x000b1;</sup>CD4<sup>+</sup>/CX3CR1<sup>+</sup>
T-cells in AVD (white bar) and TAA (black bar) patients. Statistical
comparison between percentages (mean &#x000b1; SEM) was performed
with ANOVA Student's t-test for unpaired data. Statistically
significant differences (P&#x0003c;0.05) were detected. The functional
balance (ratio) between the blood frequency of CD4<sup>+</sup>
T-lymphocytes producing IFN-&#x003b3; vs. the total fraction of
IL-17A+IL-21 cytokine-producing CD4<sup>+</sup> T-cells was
significantly lower in the TAA group (<xref ref-type="fig" rid="f5">Figure 5A</xref>).</p><p>ANOVA=analysis of variance; AVD=aortic valve disease;
IFN-&#x003b3;=interferon gamma; IL=interleukin; SEM=standard error of
the mean; TAA=thoracic aortic aneurysm</p></caption><graphic xlink:href="rbccv-34-01-0008-g04"/></fig></p><p>For each patient, the sum of
CD4<sup>+</sup>CD28<sup>&#x000b1;</sup>CD4<sup>+</sup>/CX3CR1<sup>+</sup>
T-cell fractions correlated positively with the corresponding values of the
above-mentioned cytokine ratio (<xref ref-type="fig" rid="f5">Figure
5</xref>).</p><p><fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>(A) Ratio between the blood frequency of CD4<sup>+</sup>
T-lymphocytes producing IFN-&#x003b3; vs. the total fraction of
IL-17A+IL-21 cytokine-producing CD4<sup>+</sup> T-cells in AVD
(white bar) and TAA (black bar) patients. Statistical comparison
between ratios (mean &#x000b1; SEM) was performed with ANOVA
Student's t-test for unpaired data. Statistically significant
differences (P&#x0003c;0.05) were detected. (B) Linear regression between
the individual fractions (percentages) of circulating
CD4<sup>+</sup>CD28<sup>&#x000b1;</sup>CD4<sup>+</sup>/CX3CR1<sup>+</sup>
T-cells (x axis) and the corresponding IFN-&#x003b3;/(IL-17A+IL-21)
cytokine ratios (y axis) in all patients.</p><p>ANOVA=analysis of variance; AVD=aortic valve disease;
IFN-&#x003b3;=interferon gamma; IL=interleukin; SEM=standard error of
the mean; TAA=thoracic aortic aneurysm</p></caption><graphic xlink:href="rbccv-34-01-0008-g05"/></fig></p><p>The mean value (&#x000b1; SEM) of blood Treg, expressed as a percentage of total
CD4<sup>+</sup> T-cells, was 1.19&#x000b1;0.09; no statistically significant
differences have been observed between the 2 groups of patients. The frequency
ratio of
CD4<sup>+</sup>CD28<sup>&#x000b1;</sup>CD4<sup>+</sup>/CX3CR1<sup>+</sup>
T-cells <italic>vs</italic>. circulating Treg was significantly lower in the TAA
group than in the AVD group (<xref ref-type="fig" rid="f6">Figure 6</xref>).</p><p><fig id="f6" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Frequency ratio of blood
CD4<sup>+</sup>CD28<sup>&#x000b1;</sup>CD4<sup>+</sup>/CX3CR1<sup>+</sup>
T-cells vs. Treg in AVD (white bar) and TAA (black bar) patients.
Statistical comparison between ratios (mean &#x000b1; SEM) was
performed with ANOVA Student's t-test for unpaired data.
Statistically significant differences (P&#x0003c;0.05) were detected.</p><p>ANOVA=analysis of variance; AVD=aortic valve disease; SEM=standard
error of the mean; TAA=thoracic aortic aneurysm; Treg=regulatory
T-cells</p></caption><graphic xlink:href="rbccv-34-01-0008-g06"/></fig></p></sec><sec><title>CD4<sup>+</sup> T-cells Phenotype/Function, Aortic Valve Pathology, and
Clinical Features</title><p>No correlation has been found between all the above-mentioned phenotypic and
functional CD4<sup>+</sup> T-cell features and the patients' ages. Student's
t-test and linear regression statistical analysis did not show significant
associations between immunological parameters and patients' clinical
characteristics, such as the prevalent type of valve pathology, aortic valve
mean gradient values, associated risk factors, and current medical therapies.
The mean functional ratio of IFN-&#x003b3; <italic>vs</italic>. IL-17A+IL-21
cytokine-producing CD4<sup>+</sup> T-cells was significantly higher
(<italic>P</italic>=0.0228) in female (2.144&#x000b1;279) than in male
patients (1.398&#x000b1;0.147). On the other hand, the Chi-squares statistical
analysis did not evidence a significant association between sex differences and
the presence of TAA.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Clinical and experimental studies carried out in abdominal aortic aneurysms by
histological and immunohistochemical procedures proved that a predominant
Th2-mediated immune response, mainly driven by IL-4, IL-5, or IL-10 cytokines,
induces severe aneurysm formations<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. On the other hand, a prevalent Th1-mediated
immune response, sustained by the infiltration of mononuclear cells releasing
IFN-&#x003b3; and IL-12, has been demonstrated to be responsible for transmural
inflammation and external vessel wall dilatation in ascending
TAA<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>. Nevertheless, independently of their localization,
both types of dilating aortic lesions are characterized by common histopathological
findings, also including evident modifications of ECM turnover with overexpressed
collagen deposition and fibrosis<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r4" ref-type="bibr">4</xref>]</sup>. As known, the ECM remodeling, with fibroblasts
activation and development of fibrosis, occurring in pathological conditions, such
as systemic sclerosis, atherosclerosis, parasitic infections, and after the use of
silicone mammary implants, is suppressed by a locally polarized Th1
IFN-&#x003b3;-driven immune response<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>In spite of the histological demonstration of a prevalent Th1-mediated immune
response into the wall of dilated and/or aneurysmatic ascending thoracic aortas, so
far little is known about the systemic immunological status of these patients.
Therefore, in our study, we evaluated several phenotypic and functional features of
peripheral blood CD4<sup>+</sup> T-lymphocytes in patients undergoing a cardiac
operation for aortic valve replacement associated, or not, with elective surgery for
TAA.</p><p>We have found out that the cumulative CD4<sup>+</sup> T-cell fraction calculated by
percentage addition of circulating CD4<sup>+</sup>CD28<sup>-</sup> T-cells, a subset
of cytotoxic T-lymphocytes producing large amount of
IFN-&#x003b3;<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>, plus CD4<sup>+</sup> T-cells carrying the
fractalkine receptor CX3CR1 (CD4<sup>+</sup>/CX3CR1<sup>+</sup>), preferentially
expressed on Th1 IFN-&#x003b3;-producing cells<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>, is significantly lower in the TAA
group than in the AVD group.</p><p>A prevalent pro-fibrotic IL-17A/IL-21-driven polarization of blood CD4<sup>+</sup>
T-lymphocytes in the TAA group seems to be demonstrated, in our study, by the
significantly lower mean ratio observed between the frequency of CD4<sup>+</sup>
T-lymphocytes producing the anti-fibrotic IFN-&#x003b3; <italic>vs</italic>. the
total fraction of IL-17A+IL-21 pro-fibrotic cytokine-producing CD4<sup>+</sup>
T-cells<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r31" ref-type="bibr">31</xref>,<xref rid="r32" ref-type="bibr">32</xref>]</sup>.</p><p>Previous papers demonstrated that human fibrocytes are potent antigen-presenting
cells (APC) capable of priming naive T-cells <italic>in situ</italic>
<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup>. Since
the requirement of a more broad T-cell/APC cross-talk via CD40-CD40L interactions
for generation of Th17- than for Th1 IFN-&#x003b3;-mediated inflammatory
responses<sup>[<xref rid="r34" ref-type="bibr">34</xref>,<xref rid="r35" ref-type="bibr">35</xref>]</sup>, our data suggest that the higher extent of
fibrotic tissue may orientate aneurysmatic aorta tissue-resident T-cells towards a
prevalent production of IL-17A and IL-21, so creating a self-maintaining loop for
further fibrocyte priming, collagen production, and pro-fibrotic tissue
remodeling.</p><p>The close correlation existing between the individual values of the
IFN-&#x003b3;/(IL-17A + IL-21) functional ratio and the
CD4<sup>+</sup>CD28<sup>&#x000b1;</sup>CD4<sup>+</sup>/CX3CR1<sup>+</sup> T-cell
fraction indicates that the association of these last phenotypic T-cell subsets is
strictly involved in the establishment of a prevalently IFN-&#x003b3;-oriented blood
CD4<sup>+</sup> T-cell polarization in AVD subjects without TAA.</p><p>Moreover, while previous papers showed that Treg and IL-10-producing CD4<sup>+</sup>
T-lymphocytes separately suppress collagen deposition and tissue fibrosis in several
chronic inflammatory conditions<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>, apparently cooperating with the anti-fibrotic
action of IFN-10-producing CD4<sup>+</sup> T-cells, the significantly lower ratio of
total CD4<sup>+</sup>CD28<italic><sup>&#x000b1;</sup></italic>
CD4<sup>+</sup>/CX3CR1<sup>+</sup> T-cell <italic>vs</italic>. Treg observed in
our TAA patients suggests that a tissue IFN-&#x003b3; counter-acting effect of Treg,
mainly sustained by IL-10 production<sup>[<xref rid="r36" ref-type="bibr">36</xref>]</sup>, could be detrimental for this specific
pathological condition.</p><p>Previous papers have shown that circulating T-cells represent an important repository
pool to reveal tissue-resident T-cell functional abnormalities in immune-mediated
connective pathologies, such as systemic sclerosis, characterized by a deregulated
fibroblast activation leading to fibrosis of internal organs<sup>[<xref rid="r37" ref-type="bibr">37</xref>]</sup>. Moreover, it has been
demonstrated that the evaluation of balanced dynamic inter-relationships among
different phenotypic/functional characteristics of blood CD4<sup>+</sup> T-cell
subsets can identify unique immunological features correlating with the clinical
outcome and therapeutic interventions in selected cardiovascular
patients<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>We conclude that there is a presence of an immunological imbalance in the form of
fibrocyte activation and Treg differentiation leading to the development of an
aortic aneurysm in patients with AVD. On this basis, eventually, a targeted
therapeutic model could be developed if it is confirmed in a large number of
patients with TAA, including subjects with aortic rupture/dissection.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">SS</td><td align="left" valign="top" rowspan="1" colspan="1">Work design; concept; experiments; lab
work; data acquisition; analysis; interpretation and manuscript
writing; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KKT</td><td align="left" valign="top" rowspan="1" colspan="1">Work design; concept; experiments; lab
work; data acquisition, analysis; interpretation and manuscript
writing; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SB</td><td align="left" valign="top" rowspan="1" colspan="1">Concept; data analysis; interpretation;
supervision; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PG</td><td align="left" valign="top" rowspan="1" colspan="1">Lab experiments; advice; review of
manuscript and critical appraisal; final approval of the version to
be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EK</td><td align="left" valign="top" rowspan="1" colspan="1">Supervision; addition of concept; review
of manuscript and critical appraisal; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MS</td><td align="left" valign="top" rowspan="1" colspan="1">Funding; logistic; supervision; final
approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AMM</td><td align="left" valign="top" rowspan="1" colspan="1">Concept, supervision; final revision and
approval of the manuscript; final approval of the version to be
published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the College of Medical Sciences, Teaching Hospital,
Bharatpur, Chitwan, Nepal.</p></fn><fn fn-type="financial-disclosure"><p>Financial support: This study was funded by the National Research Council (CNR)
of Italy, RSTL (Curiosity Driven Research Program) DG.RSTL.035.006-035.</p></fn><fn fn-type="other"><p>Fast Track</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS</title><p>The authors wish to express their appreciation to the personnel of the "G.
Pasquinucci" Heart Hospital operating theater, intensive care unit, and laboratory
departments.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elefteriades</surname><given-names>JA</given-names></name><name><surname>Farkas</surname><given-names>EA</given-names></name></person-group><article-title>Thoracic aortic aneurysm clinically pertinent controversies and
uncertainties</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><issue>9</issue><fpage>841</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">20185035</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bode-J&#x000e4;nisch</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>D</given-names></name><name><surname>Stuhrmann</surname><given-names>M</given-names></name><name><surname>Fieguth</surname><given-names>A</given-names></name></person-group><article-title>Aortic dissecting aneurysms: histopathological
findings</article-title><source>Forensic Sci Int</source><year>2012</year><volume>214</volume><issue>1-3</issue><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">21794994</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>LeMaire</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>YH</given-names></name><name><surname>Gan</surname><given-names>Y</given-names></name><name><surname>Bartsch</surname><given-names>H</given-names></name><etal/></person-group><article-title>Increased collagen deposition and elevated expression of
connective tissue growth factor in human thoracic aortic
dissection</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>1 Suppl</issue><fpage>I200</fpage><lpage>I205</lpage><pub-id pub-id-type="pmid">16820572</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forte</surname><given-names>A</given-names></name><name><surname>Della Corte</surname><given-names>A</given-names></name><name><surname>De Feo</surname><given-names>M</given-names></name><name><surname>Cerasuolo</surname><given-names>F</given-names></name><name><surname>Cipollaro</surname><given-names>M</given-names></name></person-group><article-title>Role of myofibroblasts in vascular remodelling: focus on
restenosis and aneurysm</article-title><source>Cardiovasc Res</source><year>2010</year><volume>88</volume><issue>3</issue><fpage>395</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">20621923</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wynn</surname><given-names>TA</given-names></name></person-group><article-title>Cellular and molecular mechanisms of fibrosis</article-title><source>J Pathol</source><year>2008</year><volume>214</volume><issue>2</issue><fpage>199</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">18161745</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wick</surname><given-names>G</given-names></name><name><surname>Backovic</surname><given-names>A</given-names></name><name><surname>Rabensteiner</surname><given-names>E</given-names></name><name><surname>Plank</surname><given-names>N</given-names></name><name><surname>Schwentner</surname><given-names>C</given-names></name><name><surname>Sgonc</surname><given-names>R</given-names></name></person-group><article-title>The immunology of fibrosis: innate and adaptive
responses</article-title><source>Trends Immunol</source><year>2010</year><volume>31</volume><issue>3</issue><fpage>110</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">20106721</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>AK</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name></person-group><article-title>Functional diversity of helper T lymphocytes</article-title><source>Nature</source><year>1996</year><volume>383</volume><issue>6603</issue><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">8893001</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>KM</given-names></name><name><surname>Stockinger</surname><given-names>B</given-names></name></person-group><article-title>Effector T cell plasticity: flexibility in the face of changing
circumstances</article-title><source>Nat Immunol</source><year>2010</year><volume>11</volume><issue>8</issue><fpage>674</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">20644573</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liuzzo</surname><given-names>G</given-names></name><name><surname>Montone</surname><given-names>RA</given-names></name><name><surname>Gabriele</surname><given-names>M</given-names></name><name><surname>Pedicino</surname><given-names>D</given-names></name><name><surname>Giglio</surname><given-names>AF</given-names></name><name><surname>Trotta</surname><given-names>F</given-names></name><etal/></person-group><article-title>Identification of unique adaptive immune system signature in
acute coronary syndromes</article-title><source>Int J Cardiol</source><year>2013</year><volume>168</volume><issue>1</issue><fpage>564</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">23391699</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zal</surname><given-names>B</given-names></name><name><surname>Kaski</surname><given-names>JC</given-names></name><name><surname>Arno</surname><given-names>G</given-names></name><name><surname>Akiyu</surname><given-names>JP</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Cole</surname><given-names>D</given-names></name><etal/></person-group><article-title>Heat-shock protein 60-reactive CD4+CD28null T cells in patients
with acute coronary syndromes</article-title><source>Circulation</source><year>2004</year><volume>109</volume><issue>10</issue><fpage>1230</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">14993140</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffrin</surname><given-names>EL</given-names></name></person-group><article-title>Immune mechanisms in hypertension and vascular
injury</article-title><source>Clin Sci (Lond)</source><year>2014</year><volume>126</volume><issue>4</issue><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">24144355</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gor</surname><given-names>DO</given-names></name><name><surname>Rose</surname><given-names>NR</given-names></name><name><surname>Greenspan</surname><given-names>NS</given-names></name></person-group><article-title>TH1-TH2: a procrustean paradigm</article-title><source>Nat Immunol</source><year>2003</year><volume>4</volume><issue>6</issue><fpage>503</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">12774069</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Mackay</surname><given-names>CR</given-names></name></person-group><article-title>Chemoattractants and their receptors in homeostasis and
inflammation</article-title><source>Curr Opin Immunol</source><year>2004</year><volume>16</volume><issue>6</issue><fpage>724</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">15511664</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayamada</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Kanno</surname><given-names>Y</given-names></name><name><surname>O'Shea</surname><given-names>JJ</given-names></name></person-group><article-title>Helper T cell diversity and plasticity</article-title><source>Curr Opin Immunol</source><year>2012</year><volume>24</volume><issue>3</issue><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">22341735</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Kuchroo</surname><given-names>VK</given-names></name></person-group><article-title>The many faces of Th17 cells</article-title><source>Curr Opin Immunol</source><year>2011</year><volume>23</volume><issue>6</issue><fpage>702</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">21899997</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulivieri</surname><given-names>C</given-names></name><name><surname>Baldari</surname><given-names>CT</given-names></name></person-group><article-title>Statins: from cholesterol-lowering drugs to novel
immunomodulators for the treatment of Th17-mediated autoimmune
diseases</article-title><source>Pharmacol Res</source><year>2014</year><volume>88</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">24657239</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platten</surname><given-names>M</given-names></name><name><surname>Youssef</surname><given-names>S</given-names></name><name><surname>Hur</surname><given-names>EM</given-names></name><name><surname>Ho</surname><given-names>PP</given-names></name><name><surname>Han</surname><given-names>MH</given-names></name><name><surname>Lanz</surname><given-names>TV</given-names></name><etal/></person-group><article-title>Blocking angiotensin-converting enzyme induces potent regulatory
T cells and modulated Th1- and Th17-mediated autoimmunity</article-title><source>Proc Natl Acad Sci U S A</source><year>2009</year><volume>106</volume><issue>35</issue><fpage>14948</fpage><lpage>14953</lpage><pub-id pub-id-type="pmid">19706421</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donato Aquaro</surname><given-names>G</given-names></name><name><surname>Ait-Ali</surname><given-names>L</given-names></name><name><surname>Basso</surname><given-names>ML</given-names></name><name><surname>Lombardi</surname><given-names>M</given-names></name><name><surname>Pingitore</surname><given-names>A</given-names></name><name><surname>Festa</surname><given-names>P</given-names></name></person-group><article-title>Elastic properties of aortic wall in patients with bicuspid
aortic valve by magnetic resonance imaging</article-title><source>Am J Cardiol</source><year>2011</year><volume>108</volume><issue>1</issue><fpage>81</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">21529726</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sbrana</surname><given-names>S</given-names></name><name><surname>Bevilacqua</surname><given-names>S</given-names></name><name><surname>Buffa</surname><given-names>M</given-names></name><name><surname>Spiller</surname><given-names>D</given-names></name><name><surname>Parri</surname><given-names>MS</given-names></name><name><surname>Gianetti</surname><given-names>J</given-names></name><etal/></person-group><article-title>Post-reperfusion changes of monocyte function in coronary blood
after extracorporeal circulation</article-title><source>Cytometry B Clin Cytom</source><year>2005</year><volume>65</volume><issue>1</issue><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15786508</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>LE</given-names></name><name><surname>Walker</surname><given-names>JM</given-names></name><name><surname>Maecker</surname><given-names>HT</given-names></name></person-group><article-title>Optimization of whole blood antigen-specific cytokine assays for
CD4(+) T cells</article-title><source>Cytometry</source><year>2000</year><volume>40</volume><issue>1</issue><fpage>60</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">10754518</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>J</given-names></name><name><surname>Bourcier</surname><given-names>K</given-names></name><name><surname>Wallace</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Conway</surname><given-names>A</given-names></name><name><surname>Seyfert-Margolis</surname><given-names>V</given-names></name><etal/></person-group><article-title>Validated protocol for FoxP3 reveals increased expression in type
1 diabetes patients</article-title><source>Cytometry B Clin Cytom</source><year>2009</year><volume>76</volume><issue>2</issue><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">18690669</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baecher-Allan</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Hafler</surname><given-names>DA</given-names></name></person-group><article-title>CD4+CD25high regulatory cells in human peripheral
blood</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><issue>3</issue><fpage>1245</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">11466340</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Provinciali</surname><given-names>M</given-names></name><name><surname>Moresi</surname><given-names>R</given-names></name><name><surname>Donnini</surname><given-names>A</given-names></name><name><surname>Lisa</surname><given-names>RM</given-names></name></person-group><article-title>Reference values for CD4+ and CD8+ T lymphocytes with
na&#x000ef;ve or memory phenotype and their association with mortality in the
elderly</article-title><source>Gerontology</source><year>2009</year><volume>55</volume><issue>3</issue><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">19190395</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>NP</given-names></name><name><surname>Akbar</surname><given-names>AN</given-names></name><name><surname>Goronzy</surname><given-names>J</given-names></name></person-group><article-title>CD28(-) T cells: their role in the age-associated decline of
immune function</article-title><source>Trends Immunol</source><year>2009</year><volume>30</volume><issue>7</issue><fpage>306</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">19540809</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>F</given-names></name><name><surname>Albert</surname><given-names>MH</given-names></name><name><surname>Arenz</surname><given-names>S</given-names></name><name><surname>Bidlingmaier</surname><given-names>C</given-names></name><name><surname>Berkowicz</surname><given-names>N</given-names></name><name><surname>Sedlaczek</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intracellular T-cell cytokine levels are age-dependent in healthy
children and adults</article-title><source>Eur Cytokine Netw</source><year>2005</year><volume>16</volume><issue>4</issue><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">16464742</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenzuela</surname><given-names>HF</given-names></name><name><surname>Effros</surname><given-names>RB</given-names></name></person-group><article-title>Divergent telomerase and CD28 expression patterns in human CD4
and CD8 T cells following repeated encounters with the same antigenic
stimulus</article-title><source>Clin Immunol</source><year>2002</year><volume>105</volume><issue>2</issue><fpage>117</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">12482386</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Shichiri</surname><given-names>M</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>RT</given-names></name><name><surname>Mitchell</surname><given-names>RN</given-names></name></person-group><article-title>Th2-predominant inflammation and blockade of IFN-gamma signaling
induce aneurysms in allografted aortas</article-title><source>J Clin Invest</source><year>2004</year><volume>114</volume><issue>2</issue><fpage>300</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">15254597</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>PC</given-names></name><name><surname>Yakimov</surname><given-names>AO</given-names></name><name><surname>Teesdale</surname><given-names>MA</given-names></name><name><surname>Coady</surname><given-names>MA</given-names></name><name><surname>Dardik</surname><given-names>A</given-names></name><name><surname>Elefteriades</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Transmural inflammation by interferon-gamma-producing T cells
correlates with outward vascular remodeling and intimal expansion of
ascending thoracic aortic aneurysm</article-title><source>FASEB J</source><year>2005</year><volume>19</volume><issue>11</issue><fpage>1528</fpage><lpage>1530</lpage><pub-id pub-id-type="pmid">16014397</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Berg</surname><given-names>PJ</given-names></name><name><surname>van Leeuwen</surname><given-names>EM</given-names></name><name><surname>ten Berge</surname><given-names>IJ</given-names></name><name><surname>van Lier</surname><given-names>R</given-names></name></person-group><article-title>Cytotoxic human CD4(+) T cell</article-title><source>Curr Opin Immunol</source><year>2008</year><volume>20</volume><issue>3</issue><fpage>339</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">18440213</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umehara</surname><given-names>H</given-names></name><name><surname>Bloom</surname><given-names>ET</given-names></name><name><surname>Okazaki</surname><given-names>T</given-names></name><name><surname>Domae</surname><given-names>N</given-names></name><name><surname>Imai</surname><given-names>T</given-names></name></person-group><article-title>Fractalkine and vascular injury</article-title><source>Trends Immunol</source><year>2001</year><volume>22</volume><issue>11</issue><fpage>602</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">11698220</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteleone</surname><given-names>G</given-names></name><name><surname>Pallone</surname><given-names>F</given-names></name><name><surname>MacDonald</surname><given-names>TT</given-names></name></person-group><article-title>Interleukin-21: a critical regulator of the balance between
effector and regulatory T-cell responses</article-title><source>Trends Immunol</source><year>2008</year><volume>29</volume><issue>6</issue><fpage>290</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">18440864</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><article-title>IL-17A plays a critical role in the pathogenesis of liver
fibrosis through hepatic stellate cell activation</article-title><source>J Immunol</source><year>2013</year><volume>191</volume><issue>4</issue><fpage>1835</fpage><lpage>1844</lpage><pub-id pub-id-type="pmid">23842754</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chesney</surname><given-names>J</given-names></name><name><surname>Bacher</surname><given-names>M</given-names></name><name><surname>Bender</surname><given-names>A</given-names></name><name><surname>Bucala</surname><given-names>R</given-names></name></person-group><article-title>The peripheral blood fibrocyte is a potent antigen-presenting
cell capable of priming naive T cells in situ</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><issue>12</issue><fpage>6307</fpage><lpage>6312</lpage><pub-id pub-id-type="pmid">9177213</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzman</surname><given-names>SD</given-names></name><name><surname>Gallo</surname><given-names>E</given-names></name><name><surname>Hoyer</surname><given-names>KK</given-names></name><name><surname>Abbas</surname><given-names>AK</given-names></name></person-group><article-title>Differential requirements for Th1 and Th17 responses to a
systemic self-antigen</article-title><source>J Immunol</source><year>2011</year><volume>186</volume><issue>8</issue><fpage>4668</fpage><lpage>4673</lpage><pub-id pub-id-type="pmid">21402892</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Kawakita</surname><given-names>A</given-names></name><name><surname>Okazaki</surname><given-names>S</given-names></name><name><surname>Yasutomi</surname><given-names>M</given-names></name><name><surname>Murai</surname><given-names>H</given-names></name><name><surname>Ohshima</surname><given-names>Y</given-names></name></person-group><article-title>IL-17A/F modulates fibrocyte functions in cooperation with
CD40-mediated signaling</article-title><source>Inflammation</source><year>2013</year><volume>36</volume><issue>4</issue><fpage>830</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">23400328</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cretney</surname><given-names>E</given-names></name><name><surname>Kallies</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>SL</given-names></name></person-group><article-title>Differentiation and function of Foxp3(+) effector regulatory T
cells</article-title><source>Trends Immunol</source><year>2013</year><volume>34</volume><issue>2</issue><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">23219401</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brembilla</surname><given-names>NC</given-names></name><name><surname>Chizzolini</surname><given-names>C</given-names></name></person-group><article-title>T cell abnormalities in systemic sclerosis with a focus on Th17
cells</article-title><source>Eur Cytokine Netw</source><year>2012</year><volume>23</volume><issue>4</issue><fpage>128</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">23360781</pub-id></element-citation></ref></ref-list></back></article>